Efficacy stem cells in improving the symptoms of patients with lupus

The therapeutic efficiency and immunogenic assessments of the placenta mesenchymal stem cell–derived exosomes on alleviation of symptoms in patients with lupus (a clinical trials)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N182

Enrollment

Registered

2022-02-16

Start date

2022-02-09

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus. Systemic lupus erythematosus (SLE)

Interventions

Intervention 1: The intervention group will receive the conventional treatment(Such as hydroxychloroquine) with exosomes derived from a single source of placenta mesenchymal stem cells (first one-tent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Class 3 or 4 resistant lupus nephritis Parenchymal lung involvement or refractory heart involvement Resistant vasculitis Resistant CNS involvement

Exclusion criteria

Exclusion criteria: Other autoimmune diseases Uncontrolled high blood pressure Diabetes and other endocrine disorders Cardiovascular failure Severe renal failure and need to dialysis Hepatic impairment Depression Endocarditis Lupus pneumonia Pregnancy and breast-feeding

Design outcomes

Primary

Measure	Time frame
Anti-Nuclear Antibody (ANA). Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: Taking blood from the arm area.;Antiphospholipid antibodies. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.;Glucose. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.;Triglyceride. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.	—

Measure

Time frame

Anti-Nuclear Antibody (ANA). Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: Taking blood from the arm area.;Antiphospholipid antibodies. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.;Glucose. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.;Triglyceride. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Famol Samavati

Kermanshah University of Medical Sciences

sh.famil.s@gmail.com+98 83 3427 6473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026